When: Q3 2026 FCF/OCF conversion recovering above 50%

Then: Upgrade to Hold on structural improvement

HOLD existing position with hard invalidation below 200-day SMA at $330.28; acceptable trim of 10-15% for taxable accounts only for rebalancing; no new short initiations

• Existing holders should not trim into strength at $351 when 200-day SMA is rising at $330.28
• Berkshire Hathaway has accumulated $24.2 billion in Alphabet with Ryanair five-year deal as flagship enterprise validation
• Q2 capex spike represents strategic AI infrastructure build-out from position of $242.5 billion cash, 2.72 current ratio, and 48.7% ROE
• Normalized P/E of 17.23 headline or 23.31 forward should not penalize successful security portfolio management
• Operating business growing 24% YoY revenue with 30% operating income growth
• Price at $343.54 sits 4% above rising 200-day SMA with RSI neutral at 45.74
• July 23 capitulation volume marked swing low with bullish MACD divergence in play
• Position sizing should be capped at benchmark weight, not underweighted during confirmed uptrend
• Hard invalidation should be $330.28 (200-day SMA), not $325, to avoid unnecessary slippage risk

→ vs aggressive: SELL recommendation is premature and asymmetric in the wrong direction; trimming 25-50% into overhead supply sells to institutions we should be aligned with; FCF argument is intellectually inconsistent using $53 billion trailing FCF as both bullish and bearish

→ vs neutral: HOLD is not a neutral act; underweights capex and debt trajectory; fails to provide clear plan for what to do if $330 actually breaks

TRIM (15-25% of position)

• Entry price at $351 offers poor risk-reward with resistance at $354.45 (less than 1% away) and stop at $325 (more than 7% away)
• Capex doubled year-over-year, debt quadrupling, FCF flipped negative, buybacks at zero
• Long-term debt of $98 billion with quarterly interest expense running nearly 5x year-ago levels
• Price sitting below four converging resistance layers with 9% decline despite constructive news
• 200 SMA rising at $330.28, serving as structural support and invalidation line
• July 23 capitulation candle at 69.4 million shares with subsequent recovery marks textbook swing low
• Bullish MACD crossover is real and presents rebound risk for aggressive trim
• Normalized forward P/E of 32 to 35 times is not a screaming buy but not fatal either
• Revenue growth of 24% and operating income growth of 30% support long-term thesis
• 86% probability of no Fed cuts in 2026 means returns must come from earnings, not multiple expansion
• Balance sheet remains fortress despite increased leverage
• Resistance zone $351-$354 is binary test: close above $354.45 flips to support with path to $377 and $400; failure targets $340 then $330
• For low cost basis under $200, trim 10 to 15 percent; for cost basis $300-$350, trim 20 to 25 percent
• Execute trim only on confirmed test and failure of resistance zone using conditional order, not market order at single price
• If price closes above $354.45 with volume, trim complete and let residual run
• If price closes below $330, exit residual and reassess

→ vs aggressive: The 50% trim recommendation overreaches by not distinguishing between position management for existing holders vs. fresh entry decisions; low cost basis holders face different calculus due to tax drag and embedded gains

→ vs aggressive: Dismisses bullish MACD crossover, rising 200 SMA, and July capitulation candle too quickly when framing the trim as measured rather than aggressive

→ vs conservative: HOLD with no trim and no plan for $330 is patience, not risk management; patience is fine until price starts to invalidate the structure

→ vs conservative: Underweights capex and FCF trajectory; fortress balance sheet with $98B long-term debt and 5x interest expense is materially different than 12 months ago

→ vs conservative: Cannot wave away normalized P/E of 32-35x; security gains are real but non-recurring and operating business is what market is pricing

→ vs conservative: Both aggressive and conservative treat $351-$354 resistance as sell or nothing, missing the asymmetry of a potential breakout that flips resistance to support